Dr. Michael Simons Is Designated as the Berliner Professor
Dr. Michael Simons, recently appointed the Robert W. Berliner Professor of Medicine, is a leader in the role of angiogenesis (the growth of new blood vessels) in cardiovascular diseases.
Simons joined the Yale faculty earlier this fall as the new section chief of cardiovascular medicine at the School of Medicine and Yale-New Haven Hospital. His research interests include fibroblast growth factor signaling in the vascular system, regulation of arterial development and branching and endothelial signaling. He is also interested in the clinical applications of biological therapies — developing strategies for delivery and assessment of various biological agents (genes, proteins, antibodies and receptor “traps”) — and in identification and validation of novel biomarkers that predict individual responses to therapeutic interventions. He has been an advocate for using growth factors to stimulate new vessel growth to improve circulation in damaged regions of the heart or in blood-deprived limbs. He is the author or co-author of more than 200 peer-reviewed research articles, review articles and book chapters.
Prior to coming to Yale, Simons was the A.G. Huber Professor of Medicine, and professor of pharmacology and toxicology, at Dartmouth Medical School. He was also chief of cardiology at Dartmouth-Hitchcock Medical Center and the director of its Cardiovascular Center and the Angiogenesis Research Center. In addition, he served on the medical center’s board of governors. While at Dartmouth, he received the Department of Medicine’s Excellence in Teaching Award.
Simons received his B.S. from the Massachusetts Institute of Technology (MIT) and his medical degree from the Yale School of Medicine in 1984. He completed his residency in internal medicine at New England Medical Center, Boston, before serving as a medical staff fellow and postdoctoral fellow in the laboratory of molecular cardiology at the National Heart, Lung and Blood Institute at the National Institutes of Health. He completed his fellowship in cardiology at Beth Israel Hospital in Boston and his postdoctoral training at MIT, where he was the associate scientist in the Program for Excellence in Molecular Biology of the Cardiovascular System.
The Yale physician is board-certified in internal medicine, cardiovascular disease and nuclear cardiology. He is the principal investigator on research grants from the National Institutes of Health totaling more than $4.5 million in direct costs.